Last reviewed · How we verify
NCT04363255
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Status unknown
Phase 2
Last updated 28 April 2020
What this trial tests
Phase 2 trial testing Etoposide Injection in Small Cell Lung Carcinoma in 20 participants. Status unknown.
Timeline
1 May 2020
Primary endpoint
31 December 2022
31 December 2022
31 March 2023
Quick facts
| Lead sponsor | Taizhou Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 March 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Etoposide Injection
- Carboplatin Injection — full drug profile →
- Cisplatin injection — full drug profile →
- Toripalimab (TORIPALIMAB) — full drug profile →
- Anlotinib hydrochloride
Conditions studied
- Small Cell Lung Carcinoma — all drugs for Small Cell Lung Carcinoma →
Sponsor
Taizhou Hospital
Who can join
18 and older, any sex, with Small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Cani M, Napoli VM, Garbo E, Ferrari G, et al · · 2023 · cited 11× · PMID 37240229 · DOI 10.3390/ijms24108883 -
Toxicities of Immunotherapy for Small Cell Lung Cancer.
Fu Y, Zheng Y, Wang PP, Ding ZY. · · 2021 · cited 9× · PMID 34136376 · DOI 10.3389/fonc.2021.603658 -
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors.
Kareff SA, Samtani S, Burotto M, Prasad V, et al · · 2021 · cited 3× · PMID 34590006 · DOI 10.1016/j.jtocrr.2021.100149 -
Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients.
Tian J, Sui L, Wang H, Chen X. · · 2023 · cited 2× · PMID 37469402 · DOI 10.3389/fonc.2023.1180735 -
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
Lv D, Zhu R, Wu G, Zhang Y, et al · · 2026 · PMID 41825180 · DOI 10.1016/j.lungcan.2026.109371
Verify or expand the search:
- PubMed search for NCT04363255
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Etoposide Injection
Trials testing the same drug.
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT06786312 — A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regime · Phase 2 · not yet recruiting
- NCT06792253 — Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 3 · recruiting
- NCT06157827 — A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06164327 — Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · unknown
Other recruiting trials for Small Cell Lung Carcinoma
Currently open trials in the same condition.
- NCT07015892 — Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial · Phase 3 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07006727 — Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · Phase 1 · recruiting
- NCT06992609 — Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. · Phase 3 · recruiting
Other Taizhou Hospital trials
Trials by the same sponsor.
- NCT06997614 — Enhancing Critical Thinking Competency and Nursing Quality in Critically Ill Patient Care · NA · completed
- NCT06902935 — Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four · not yet recruiting
- NCT06441344 — Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell · Phase 3 · not yet recruiting
- NCT07127809 — Mindfulness-Based Intervention Targeting Psychological Capital to Reduce Job Burnout Among Nurses · NA · completed
- NCT06319950 — High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04363255 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taizhou Hospital
- Last refreshed: 28 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04363255.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing